Inflammatory bowel disease (IBD) includes Crohn’s disease (CD) and ulcerative colitis (UC). These are chronic autoimmune diseases of unknown etiology affecting the gastrointestinal tract. The IBD population includes a heterogeneous group of patients with varying disease courses requiring personalized treatment protocols. The complexity of the disease often delays the diagnosis and the initiation of appropriate treatments. In a subset of patients, IBD leads to colitis-associated cancer (CAC). MicroRNAs are single-stranded regulatory noncoding RNAs of 18 to 22 nucleotides with putative roles in the pathogenesis of IBD and colorectal cancer. They have been explored as biomarkers and therapeutic targets. Both tissue-derived and circulating microRNAs have emerged as promising biomarkers in the differential diagnosis and in the prognosis of disease severity of IBD as well as predictive biomarkers in drug resistance. In addition, knowledge of the cellular localization of differentially expressed microRNAs is a prerequisite for deciphering the biological role of these important epigenetic regulators and the cellular localization may even contribute to an alternative repertoire of biomarkers. In this review, we discuss findings based on RT-qPCR, microarray profiling, next generation sequencing and in situ hybridization of microRNA biomarkers identified in the circulation and in tissue biopsies.
Ulcerative colitis (UC) and Crohn’s disease (CD) are two different disorders that constitute inflammatory bowel disease (IBD). The prevalence of IBD is increasing worldwide, affecting millions of individuals. The objective of this review is to present the evolving changes in the epidemiology when looking at disease occurrence in the East compared to the West based on the most recent data. The highest incidences and prevalences are found in Northern Europe and Northern America. The incidence and prevalence in Asia are rapidly increasing, however still at a low level compared to the West. The disease courses do not differ initially. The rate of surgical treatment has declined over time. Mortality figures might be slightly more favourable in the East. Both CD and UC patients are at an increased risk for developing cancer of the gastrointestinal tract compared to the general population. The prevalence of IBD is rapidly increasing due to chronicity with a lack of cure, the young age of onset, and low mortality and it may rise exponentially due to increasing incidence and population ageing. As the number of reports on the epidemiology in the East is increasing we can foresee an evolution of the IBD epidemiology influenced by the findings in Asia adding information on the epidemiology of IBD and possibly also on the environmental factors influencing the occurrence and course of IBD.